EpiThany, Inc.

Tumor vaccine company

EpiThany, founded by Bill Watt and Mary Disis in 2014, is dedicated to the advancement of innovative therapies to improve the lives of cancer patients. EpiThany's technology enables the targeting of a multitude of tumor antigens across a spectrum of cancers, driving Th1-selective (tumor-eradicating) immune responses. EpiThany was launched in 2014 on the R&D platform developed at the Tumor Vaccine Group (TVG) at the University of Washington by pioneering cancer vaccine researcher Nora Disis, scientific co-founder of the company.